Antiphospholipid syndrome and pregnancy

Area of Science:

• Obstetrics and Gynecology
• Immunology
• Reproductive Medicine

Background:

• Antiphospholipid antibodies (aPL) have been associated with recurrent pregnancy loss since the 1960s.
• Pregnancy complications like pre-eclampsia and placental insufficiency are recognized in antiphospholipid syndrome (APS).
• Antibody characteristics (titer, isotype, antigen specificity) may influence pregnancy risk.

Purpose of the Study:

• To review the role of antiphospholipid antibodies in pregnancy complications.
• To discuss the pathogenesis of pregnancy failures in antiphospholipid syndrome.
• To highlight the impact of risk stratification and modern management on patient outcomes.

Main Methods:

• Review of historical data and current literature on antiphospholipid antibodies and pregnancy.
• Analysis of pathogenic mechanisms, including thrombotic and direct antibody effects on the placenta.
• Examination of evidence from experimental animal models (lupus-prone and naive mice).

Main Results:

• Antiphospholipid antibodies contribute to pregnancy failures through thrombotic events and direct placental effects.
• Animal models confirm the pathogenic role of aPL in pregnancy complications.
• Classification of pregnant APS patients as 'high risk' has improved prognosis.

Conclusions:

• Effective obstetric monitoring and therapy have transformed the outlook for pregnant patients with antiphospholipid syndrome.
• Despite inherent risks, successful pregnancy outcomes are now achievable in most cases.
• Understanding antibody characteristics is crucial for accurate risk assessment in APS pregnancies.